Gene info: ID 4205

Gene: MEF2A

GENE ID: 4205

Synonyms: ADCAD1|RSRFC4|RSRFC9|mef2

Description: myocyte enhancer factor 2A

Gene type: protein-coding

Location: 15q26.3

dbXrefs: Ensembl:ENSG00000068305 MIM:600660 Vega:OTTHUMG00000171937 UniprotKB:Q02078

RefSeq: NG_016443.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 9.010e-1 (AD) 5.920e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MKL2	0.939
FBXO11	0.933
RAPGEF2	0.93
TOPBP1	0.929
ARFGEF1	0.928
HEATR5B	0.927
CEP68	0.925
UBXN2B	0.924
RASAL2	0.922
KRIT1	0.921

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
S100A1	-0.477
OR4F5	-0.431
BCL7C	-0.425
OR4F29	-0.408
RBP1	-0.396
RARRES2	-0.395
HMX1	-0.389
HEY2	-0.384
S100A14	-0.38
COPZ2	-0.38

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MEF2A mRNA"	25270620
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEF2A mRNA"	19167446
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
C075773	4-phenylbutyric acid	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
C075773	4-phenylbutyric acid	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
C075773	4-phenylbutyric acid	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
C075773	4-phenylbutyric acid	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in increased expression of MEF2A mRNA	26690555\|2906747
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of MEF2A gene	28458013
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of MEF2A mRNA	16631469
D001374	Azacitidine	Azacitidine affects the expression of MEF2A protein	19002953
D001374	Azacitidine	Azacitidine results in increased expression of MEF2A	12094073
C547126	AZM551248	AZM551248 results in decreased expression of MEF2A mRNA	22323515
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MEF2A mRNA"	19150397\|2001819
D004958	Estradiol	Estradiol affects the expression of MEF2A mRNA	15598610
C006780	bisphenol A	bisphenol A results in increased expression of MEF2A mRNA	29275510
C006780	bisphenol A	bisphenol A results in increased expression of MEF2A mRNA	29097150
D019328	Buthionine Sulfoximine	Buthionine Sulfoximine results in increased expression of MEF2A mRNA	15878706
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of MEF2A mRNA	26472689
D002110	Caffeine	Caffeine results in increased expression of MEF2A mRNA	25093688
D002110	Caffeine	Caffeine results in increased expression of MEF2A protein	25093688
D002110	Caffeine	Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]	25093688
D002110	Caffeine	Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein]	25093688
D002220	Carbamazepine	Carbamazepine affects the expression of MEF2A mRNA	24752500
D002737	Chloroprene	Chloroprene results in increased expression of MEF2A mRNA	23125180
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MEF2A gene	20938992
D003042	Cocaine	Cocaine results in increased expression of MEF2A mRNA	17898221
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of MEF2A mRNA	19789285
D019327	Copper Sulfate	Copper Sulfate results in increased expression of MEF2A mRNA	19789285
D003375	Coumestrol	"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEF2A mRNA"	19167446
D003375	Coumestrol	Coumestrol results in decreased expression of MEF2A mRNA	19167446
D003471	Cuprizone	Cuprizone results in decreased expression of MEF2A mRNA	26577399
D016572	Cyclosporine	Cyclosporine results in decreased methylation of MEF2A promoter	27989131
D016572	Cyclosporine	Cyclosporine results in increased expression of MEF2A mRNA	20106945
D003620	Dantrolene	Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]	25093688
D003620	Dantrolene	Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein]	25093688
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of MEF2A mRNA	21266533
D004008	Diclofenac	Diclofenac affects the expression of MEF2A mRNA	24752500
D004041	Dietary Fats	Dietary Fats results in decreased expression of MEF2A mRNA	18042831
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MEF2A mRNA"	22485181
D019813	1,2-Dimethylhydrazine	"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of MEF2A mRNA"	27840820
D004147	Dioxins	Dioxins affects the expression of MEF2A mRNA	20463971
D004317	Doxorubicin	Doxorubicin results in increased expression of MEF2A mRNA	16001973
C100264	enniatins	enniatins results in decreased expression of MEF2A mRNA	27163883
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MEF2A mRNA	29097150
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MEF2A gene	20938992
D005944	Glucosamine	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D005944	Glucosamine	ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D005944	Glucosamine	Glucosamine results in decreased expression of MEF2A mRNA	20165829
D005944	Glucosamine	Glucosamine results in decreased expression of MEF2A protein	20165829
D005944	Glucosamine	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D005944	Glucosamine	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D005944	Glucosamine	ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D005944	Glucosamine	Glucosamine results in decreased expression of MEF2A mRNA	20165829
D005944	Glucosamine	Glucosamine results in decreased expression of MEF2A protein	20165829
D005944	Glucosamine	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
D005944	Glucosamine	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
C089796	hexabromocyclododecane	hexabromocyclododecane results in increased expression of MEF2A mRNA	26476318
C089796	hexabromocyclododecane	hexabromocyclododecane results in increased expression of MEF2A protein	26476318
C089796	hexabromocyclododecane	MIR1 mRNA affects the reaction [hexabromocyclododecane results in increased expression of MEF2A mRNA]	26476318
C089796	hexabromocyclododecane	MIR1 mRNA affects the reaction [hexabromocyclododecane results in increased expression of MEF2A protein]	26476318
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MEF2A mRNA	25613284
C008261	lead acetate	lead acetate affects the expression of MEF2A mRNA	21829687
C045463	leflunomide	leflunomide results in increased expression of MEF2A mRNA	28988120
D058185	Magnetite Nanoparticles	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of MEF2A mRNA	21641980
D008687	Metformin	Metformin results in increased expression of MEF2A mRNA	15864539
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MEF2A gene	20938992
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of MEF2A mRNA	28001369
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of MEF2A mRNA	29104120
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of MEF2A mRNA"	26251327
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of MEF2A mRNA"	20188158
D008790	Metoprolol	Metoprolol inhibits the reaction [MEF2A protein binds to CPT1B promoter]	19233164
D008790	Metoprolol	Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]	19233164
D009151	Mustard Gas	Mustard Gas results in increased expression of MEF2A mRNA	15674843\|1895507
D009532	Nickel	Nickel affects the expression of MEF2A mRNA	14575637
D009532	Nickel	trichostatin A inhibits the reaction [Nickel affects the expression of MEF2A mRNA]	14575637
C028007	nickel monoxide	nickel monoxide results in decreased expression of MEF2A mRNA	19167457
D009569	Nitric Oxide	Nitric Oxide deficiency results in decreased expression of MEF2A mRNA	15878706
D010100	Oxygen	Oxygen deficiency results in increased expression of MEF2A mRNA	26516004
D010121	Oxytocin	MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA]	29104011
D010121	Oxytocin	MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein]	29104011
D000073878	Palm Oil	Palm Oil results in decreased expression of MEF2A mRNA	18042831
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of MEF2A mRNA	18593933
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of MEF2A mRNA	28973697
D010634	Phenobarbital	Phenobarbital affects the expression of MEF2A mRNA	23091169
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of MEF2A mRNA	26272509
C045950	propiconazole	propiconazole results in decreased expression of MEF2A mRNA	21278054
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of MEF2A mRNA	19059307
C009277	sodium arsenate	sodium arsenate results in increased expression of MEF2A mRNA	21795629
C017947	sodium arsenite	sodium arsenite results in increased expression of MEF2A mRNA	25089838
C017947	sodium arsenite	sodium arsenite results in increased expression of MEF2A protein	25089838
D053260	Soot	Soot affects the methylation of MEF2A promoter	25395096
D053260	Soot	[Soot co-treated with Sulfates] affects the methylation of MEF2A promoter	25395096
D004113	Succimer	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of MEF2A mRNA	21641980
D013431	Sulfates	[Soot co-treated with Sulfates] affects the methylation of MEF2A promoter	25395096
D013629	Tamoxifen	[Tamoxifen co-treated with ESR2 protein] results in decreased expression of MEF2A mRNA	19059307
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]	20165829
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]	20165829
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of MEF2A mRNA	20106945\|2163298
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of MEF2A mRNA	24058054
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MEF2A mRNA	25613284
D013806	Theophylline	Theophylline results in decreased expression of MEF2A mRNA	18951874
D019772	Topotecan	Topotecan results in decreased expression of MEF2A mRNA	25729387
C483909	torcetrapib	torcetrapib results in increased expression of MEF2A mRNA	23228038
C012589	trichostatin A	trichostatin A inhibits the reaction [Nickel affects the expression of MEF2A mRNA]	14575637
D014520	Urethane	Urethane results in increased expression of MEF2A mRNA	28818685
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEF2A mRNA"	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of MEF2A mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in decreased methylation of MEF2A gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased methylation of MEF2A gene	28853863
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of MEF2A gene	25560391
C025643	vinclozolin	vinclozolin affects the expression of MEF2A mRNA	19015723
C111237	vorinostat	vorinostat results in decreased expression of MEF2A mRNA	27188386
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of MEF2A mRNA	18593933

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000977	RNA polymerase II regulatory region sequence-specific DNA binding	-	IDA	20590529
GO:0000978	RNA polymerase II proximal promoter sequence-specific DNA binding	-	IBA	21873635
GO:0000978	RNA polymerase II proximal promoter sequence-specific DNA binding	-	IDA	7760790
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	IDA	10748098 16484498 20590529
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	ISA	-
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	ISM	19274049
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	NAS	19274049
GO:0001077	transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding	-	IBA	21873635
GO:0001077	transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding	-	IDA	7760790
GO:0001085	RNA polymerase II transcription factor binding	-	IPI	15466416
GO:0001102	RNA polymerase II activating transcription factor binding	-	IBA	21873635
GO:0001205	transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific DNA binding	-	IBA	21873635
GO:0003682	chromatin binding	-	IDA	21468593
GO:0003700	DNA-binding transcription factor activity	-	IDA	16043483
GO:0003705	transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding	-	IEA	-
GO:0003713	transcription coactivator activity	-	IDA	15466416
GO:0005515	protein binding	-	IPI	15466416 16043483
GO:0005515	protein binding	contributes_to	IPI	16043483
GO:0019901	protein kinase binding	-	IEA	-
GO:0033613	activating transcription factor binding	-	IPI	20590529
GO:0035035	histone acetyltransferase binding	-	IPI	20590529
GO:0042826	histone deacetylase binding	-	IBA	21873635
GO:0042826	histone deacetylase binding	-	IPI	10748098 20590529
GO:0043565	sequence-specific DNA binding	-	IDA	10835359
GO:0046332	SMAD binding	-	IPI	11160896
GO:0046982	protein heterodimerization activity	-	IPI	9858528

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000002	mitochondrial genome maintenance	-	ISS	-
GO:0000122	negative regulation of transcription by RNA polymerase II	-	IDA	16484498
GO:0000165	MAPK cascade	-	IDA	9858528
GO:0006351	transcription, DNA-templated	-	IDA	16043483
GO:0006366	transcription by RNA polymerase II	-	IEA	-
GO:0006915	apoptotic process	-	IEA	-
GO:0007507	heart development	-	IEP	10458488
GO:0007517	muscle organ development	-	NAS	1516833
GO:0010613	positive regulation of cardiac muscle hypertrophy	-	IDA	24161931
GO:0010613	positive regulation of cardiac muscle hypertrophy	-	IGI	24161931
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IDA	7760790 9858528 10748098 15466416 20590529 21468593
GO:0046326	positive regulation of glucose import	-	IEA	-
GO:0048311	mitochondrion distribution	-	ISS	-
GO:0048813	dendrite morphogenesis	-	ISS	-
GO:0051149	positive regulation of muscle cell differentiation	-	TAS	-
GO:0055005	ventricular cardiac myofibril assembly	-	ISS	-
GO:0061337	cardiac conduction	-	ISS	-
GO:0070375	ERK5 cascade	-	IMP	15132737
GO:0071277	cellular response to calcium ion	-	IDA	16484498

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000790	nuclear chromatin	-	IBA	21873635
GO:0000790	nuclear chromatin	-	ISS	-
GO:0005634	nucleus	-	IDA	16484498 20590529
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005667	transcription factor complex	-	IDA	16043483
GO:0005829	cytosol	-	IDA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	IEA
R-HSA-162582	Signal Transduction	IEA
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	IEA
R-HSA-166058	MyD88:Mal cascade initiated on plasma membrane	IEA
R-HSA-166166	MyD88-independent TLR4 cascade	IEA
R-HSA-166520	Signaling by NTRKs	IEA
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	IEA
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	IEA
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	IEA
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	IEA
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	IEA
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	IEA
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	IEA
R-HSA-168249	Innate Immune System	IEA
R-HSA-168256	Immune System	IEA
R-HSA-168898	Toll-Like Receptors Cascades	IEA
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	IEA
R-HSA-187037	Signaling by NTRK1 (TRKA)	IEA
R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	IEA
R-HSA-198753	ERK/MAPK targets	IEA
R-HSA-375170	CDO in myogenesis	TAS
R-HSA-448424	Interleukin-17 signaling	IEA
R-HSA-449147	Signaling by Interleukins	IEA
R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	IEA
R-HSA-450294	MAP kinase activation	IEA
R-HSA-525793	Myogenesis	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	IEA
R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	IEA
R-HSA-975155	MyD88 dependent cascade initiated on endosome	IEA
R-HSA-975871	MyD88 cascade initiated on plasma membrane	IEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
17579569	Relationship of the CAG repeat polymorphism of the MEF2A gene and coronary artery disease in a Chinese population. (2007)	Han Y	Clin Chem Lab Med